Screening for thrombophilia;Gli screening per trombofilia

Rivista di Medicina di Laboratorio

Volumn 5, Issue 2, 2004, Pages 118-120

  Testa, Sophie ^a,b   Antonucci, G ^a   Intra, E ^a   Martini, G ^a   Pedrini, S ^a   Alatri, A ^a   Bader, R ^a   Manzato, F ^a  

^a Gruppo di Studio Coagulazione SIMeL   (Italy)

^b CREMONA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN; ANTITHROMBIN III; BETA2 GLYCOPROTEIN 1 ANTIBODY; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; CARDIOLIPIN ANTIBODY; FIBRINOGEN; HOMOCYSTEINE; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; PROTEIN C; PROTEIN S; PROTHROMBIN;

ARTICLE; COUNSELING; GENE MUTATION; HUMAN; PARTIAL THROMBOPLASTIN TIME; PREVALENCE; PROTHROMBIN TIME; RISK FACTOR; SCREENING; THROMBOPHILIA;

EID: 4544269111     PISSN: 15923479     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Smellie WS. Appropriateness of test use in pathology: a new era or reinventing the wheel? Ann Clin Biochem 2003; 40:85-92.
2. Lane DA, Mannucci PM, Bauerb KA, Bertina RM, Bochkov NO, Boulyejenkov V, et al. Inherited thrombophilia. Part I. Thromb Haemost 1996; 76:651-2.
3. Martinelli I. Pros and cons of thrombophilia testing: pros. J Thromb Haemost 2003; 1: 410-1.
4. Machin SJ. Pros and cons of thrombophilia testing: cons. J Thromb Haemost 2003; 1:412-3.
5. Martinelli I. Rebuttal to: pros e cons of thrombophilia testing. J Thromb Haemost 2003; 1:1311-32.
6. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients with homozygous factor V Leiden (activated protein C resistance). Blood 1995; 85:1504-8.
7. Lindmarker P, Shulman S, Sten-Linder M, Wiman B, Egberg N, Johnsson H. The risk of recurrent venous thromboembolism in carriers and non carriers of the G1691A allele in the coagulation factor V gene and the G1691A allele in the prothrmbin gene. Thromb Haemost 1999; 81:684-9.
8. Carraro P; European Communities Confederation of Clinical Chemistry and Laboratory Medicine, Working Group on Guidelines for Investigation of Disease. Guidelines for the laboratory investigation of inherited thrombophilias. Recommendations for the first level clinical laboratories. Clin Chem Lab Med 2003; 41:382-91.
9. Carraro P, Simioni P. Appropriateness of choice and interpretation of tests for thrombophilic defects: a practical experience. Clin Chim Acta. 2003; 333:91-3.
10. Martinelli I. Risk factors in venous thromboemolism. Thromb Haemost 2001; 86:395-403.
11. Rosendaal FR, Helmerhost FM, Vandenbroucke JP. Oral contraceptives, hormone replacement therapy and thrombosis. Thromb Haemost 2001; 86:112-3.
12. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who carriers of factor V Leiden mutation. Lancet 1994; 344:1453-7.
13. Gruppo di Lavoro per le Linee Guida sul Trombombolismo Venoso della SISET (Società Italiana per lo Studio dell'Emostasi e Trombosi). Lo studio della trombofilia. Haematologica 2003; 88:28-46.
14. Goldhaber SZ, Visani L, Rosa M for ICOPER. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999; 353:1386-9.
15. Mannucci PM. The measurement of multifactorial thrombophilia. Thromb Haemost 2002; 88:1-2.